UY27132A1 - Naftostirilos - Google Patents

Naftostirilos

Info

Publication number
UY27132A1
UY27132A1 UY27132A UY27132A UY27132A1 UY 27132 A1 UY27132 A1 UY 27132A1 UY 27132 A UY27132 A UY 27132A UY 27132 A UY27132 A UY 27132A UY 27132 A1 UY27132 A1 UY 27132A1
Authority
UY
Uruguay
Prior art keywords
compounds
presented
formula
treatment
cancer
Prior art date
Application number
UY27132A
Other languages
English (en)
Inventor
C Yi
D Apostolos
K F Martin
L Jin-Jun
L Kin Chun
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY27132A1 publication Critical patent/UY27132A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se presentan nuevos naftostirilos de fórmula I. Estos compuestos inhiben las quinasas dependientes de ciclina (CDKs), en particular CDK2. Estos compuestos y sus sales y ésteres farmacéuticamente aceptables son agentes anti - proliferativos útiles en el tratamiento o control de desórdenes celulares proliferativos, en particular cáncer. También se presentan composiciones farmacéuticas que contienen estos compuestos, métodos para el tratamiento y/o prevención de cáncer usando estas composiciones, e intermediarios útiles en la preparación de los compuestos de fórmula I.
UY27132A 2001-01-23 2002-01-22 Naftostirilos UY27132A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26365801P 2001-01-23 2001-01-23

Publications (1)

Publication Number Publication Date
UY27132A1 true UY27132A1 (es) 2002-07-31

Family

ID=23002712

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27132A UY27132A1 (es) 2001-01-23 2002-01-22 Naftostirilos

Country Status (17)

Country Link
US (2) US6504034B2 (es)
EP (1) EP1358180B1 (es)
JP (1) JP4091434B2 (es)
KR (1) KR100563429B1 (es)
CN (1) CN1231479C (es)
AR (1) AR035738A1 (es)
AT (1) ATE283852T1 (es)
AU (1) AU2002240905B2 (es)
BR (1) BR0206621A (es)
CA (1) CA2434381C (es)
DE (1) DE60202131T2 (es)
ES (1) ES2232736T3 (es)
MX (1) MXPA03006423A (es)
PE (1) PE20020916A1 (es)
UY (1) UY27132A1 (es)
WO (1) WO2002059109A2 (es)
ZA (1) ZA200305383B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011525915A (ja) * 2008-06-26 2011-09-29 アムジエン・インコーポレーテツド キナーゼ阻害薬としてのアルキニルアルコール類
CN109665987B (zh) * 2018-12-28 2022-02-18 河南大学 萘内酰亚胺-多胺缀合物及其制备方法和用途
CA3130469A1 (en) * 2019-04-12 2020-10-15 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos
AU2021361043A1 (en) * 2020-10-14 2023-06-08 C4 Therapeutics, Inc. Tricyclic ligands for degradation of ikzf2 or ikzf4
WO2023154417A1 (en) * 2022-02-09 2023-08-17 C4 Therapeutics, Inc. Morphic forms of cft7455 and methods of manufacture thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5081131A (en) * 1986-01-13 1992-01-14 American Cyanamid Company Omega-((hetero)alkyl)benz(cd)-indol-2-amines
KR930011300B1 (ko) 1989-07-25 1993-11-29 다이호오 야꾸힌 고오교오 가부시끼가이샤 옥시인돌유도체
WO1992007830A2 (en) 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
FR2694004B1 (fr) 1992-07-21 1994-08-26 Adir Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
GB9313638D0 (en) 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
GB9423997D0 (en) 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
GB9507298D0 (en) 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DE29513441U1 (de) 1995-08-22 1995-10-19 Engelhardt, Rolf, 45883 Gelsenkirchen Aschenbecher zum Mitführen
AU4155697A (en) 1996-08-23 1998-03-06 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US5750556A (en) * 1996-10-30 1998-05-12 American Home Products Corporation 2-(aminomethyl)-3,4,7,9-tetrahydro-2H-pyrano- 2,3-E!indol-8-ones and derivatives
WO1998050356A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
JP2002532492A (ja) 1998-12-17 2002-10-02 エフ．ホフマン−ラ ロシュ アーゲー サイクリン−依存性キナーゼ、特にｃｄｋ２のインヒビターとしての４−アルケニル（及びアルキニル）オキシドール

Also Published As

Publication number Publication date
DE60202131D1 (de) 2005-01-05
US6504034B2 (en) 2003-01-07
KR100563429B1 (ko) 2006-03-22
CA2434381C (en) 2009-11-24
ZA200305383B (en) 2004-10-11
WO2002059109A3 (en) 2002-09-19
PE20020916A1 (es) 2002-10-21
DE60202131T2 (de) 2005-12-01
ATE283852T1 (de) 2004-12-15
CA2434381A1 (en) 2002-08-01
JP4091434B2 (ja) 2008-05-28
CN1487931A (zh) 2004-04-07
US20020147343A1 (en) 2002-10-10
CN1231479C (zh) 2005-12-14
EP1358180B1 (en) 2004-12-01
US6531598B1 (en) 2003-03-11
JP2004517150A (ja) 2004-06-10
BR0206621A (pt) 2004-02-25
EP1358180A2 (en) 2003-11-05
WO2002059109A2 (en) 2002-08-01
MXPA03006423A (es) 2003-10-15
AU2002240905B2 (en) 2007-03-01
AR035738A1 (es) 2004-07-07
KR20030069223A (ko) 2003-08-25
ES2232736T3 (es) 2005-06-01

Similar Documents

Publication Publication Date Title
PA8537501A1 (es) Naftostirilos
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
SV1999000016A (es) Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
SV2004001459A (es) 2- (piridin-2-ilamino) -pirido [2,3-d]pirimidin-7-onas ref. pc20501
ES2139959T3 (es) Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2.
NO20053775L (no) Diazepinoindol derivater som kinaseinhibitorer.
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
ECSP055640A (es) Composiciones de pirazol útiles como inhibidores de gsk-3
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
UY28708A1 (es) Heterociclos sustituídos y usos de los mismos
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
CR7882A (es) Compuestos 2-(1H-Indazol-6-ilamino-benzamidas como inhibidores proteinquinasas utiles para el tratamiento de enfermedades oftalmicas
AR063097A1 (es) Pirazolopirimidinas[1,5-a] inhibidoras de quinasas dependientes de ciclina(cdk), composiciones farmaceuticas que las contienen y usos en el tratamiento de enfermedades proliferativas
PA8609201A1 (es) Piridinonas sustituidas
ECSP056246A (es) DERIVADOS DE PIRROLO [3,4-c]PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA
UY31027A1 (es) Derivados de tetrahidroindol y tetrahidroindazol
ECSP066763A (es) Pirazolopirimidinas novedosas como inhibidores de quinasa ciclina-dependientes
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
UY28671A1 (es) Pirido(2.3-d)pirimidina-2,4-diaminas como inhibidores de pde 2
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
ECSP11005642A (es) Nuevos pirazolopirimidinas como inhibidores de quinasa dependientes de ciclinas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141111